NBC Universal, Inc.

As America rides a surging wave of GLP-1 medications like Ozempic and Wegovy, new questions are emerging about how long the treatments last and what happens when patients stop taking them.

Despite previous excitement around a potential link between GLP-1 drugs and a reduced risk of cancer, new research suggests the popular medications “probably have little or no effect” on a person’s risk of developing one of the 13 obesity-related cancers.

The findings, published Monday in the Annals of Internal Medicine , may seem counterintuitive, said co-author Dr. Cho-Han Chiang, who conducted the study earlier this year as an internal medicine resident at Mount Auburn Hospital, a Harvard Medical School teaching hospital in Cambridge, Massachusetts.

Stream Philadelphia News

See Full Page